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Sunnnary Data collected by the Cancer Registry of the Swiss Canton of Vaud (whose population in 1980 was
about 530,000 inhabitants) were used to estimate the incidence of second metachronous primary cancers
following any specific neoplasm. Among 34, 615 cases of incident neoplasms registered between 1974 and 1989
and followed through integrated active follow-up to the end of 1989, for a total of 118,241 person-years at
risk, there were 2,185 second primaries (1,280 males, 905 females). For both sexes, the standardised incidence
ratios (SIR) were significantly elevated by about 20%. Overall significantly elevated ratios were registered for
cancers of the oral cavity and pharynx (SIR = 1.6 for males, 2.0 for females), oesophagus in males (SIR = 1.5),
lung in males (SIR = 1.4), skin melanoma (SIR = 1.7 for males, 1.5 for females), non-melanomatous skin
cancers (SIR = 1.6 for males, 1.5 for females), female breast (SIR = 1.3), kidney (SIR = 1.5 for males, 1.9 for
females), and thyroid in males (SIR = 2.4). When specific first cancer sites were considered, the SIR following
a cancer of the oral cavity and pharynx was around 3 in both sexes, mainly on account of a substantial excess
of second primaries of the oral cavity, oesophagus, larynx and lung. The overall SIR following laryngeal
cancer was 3.0, and significant excesses were observed for oral cavity and pharynx, oesophagus and lung. After
lung cancer, the overall SIR was 1.7 for males and 2.6 for females, and significantly elevated SIRs were
observed for oral cavity, lung and oesophagus. Following non-melanomatous skin cancers, elevated SIRs were
observed in both sexes for skin melanoma and non-melanomas. The incidence of any cancer after breast
cancer was significantly elevated (SIR = 1.2), mainly on account of an elevated risk of subsequent breast
cancer (SIR = 1.7). With reference to cervical cancer, there was a significant excess for any subsequent primary(SIR = 1.6), and for lung cancer (SIR = 7.8). Significantly elevated SIRs were observed for kidney following
bladder cancer, and for bladder after kidney cancer. In both sexes, the incidence of cancers of any site was
elevated following leukaemias (SIR = 1.7 for males, 2.5 for females), and a significant excess was registered for
lung in males and non-melanomatous skin cancers in both sexes. Some of the associations observed can be
related to common risk factor exposure, such as tobacco (and alcohol) for multiple primaries of the upper
digestive and respiratory tract, or tobacco for the excess of lung cancer following bladder and probably
cervical cancer. However, the overall excess risk of a second primary cancer is relatively limited, and at least in
part attributable to increased surveillance.
There are several reports of multiple primary cancers, mostly
based on clinical or autopsy series (Berg, 1967, 1970; Schot-
tenfeld, 1969, 1971; Watanabe et al., 1984). These have sug-
gested elevated rates due to common aetiological factors (e.g.
for tobacco or diet-related cancers), or the consequences of
treatment (e.g., high leukaemia risk following treatment of
Hodgkin's disease, cervical, ovarian cancer, kidney or other
neoplasms) (Boice et al., 1985a; Boivin et al., 1986; Kaldor et
al., 1987, 1990a, 1990b).
There are, however, only a few published series including
systematic overviews of multiple primary cancers from cancer
registration schemes, including one from Denmark (1943-80;
Storm et al., 1985), one from Connecticut (1935-82; Curtis
et al., 1985; see also US Department of Health and Human
Services, 1985), and one from Finland (1953-79; Teppo et
al., 1985). Although several patterns of associations were
similar in these studies, there were various quantitative
differences: for instance, in Connecticut cancer patients had
an overall 31% increased risk of developing a subsequent
cancer, whereas no excess risk was observed in Denmark or
Finland.
Differences in study methodology may explain at least part
of these apparent discrepancies, but it is also possible that
the impact of common genetic susceptibility and environmen-
tal factors, such as aetiologic aspects and/or consequences of
cancer treatment are different in various populations (Boice
et al., 1985b). Thus, to provide further quantitative infor-
mation on the issue, we present in this paper a summary
overview of multiple primary cancers registered in the Swiss
Vaud Cancer Registry from 1974 to 1989.
Materials and methods
The data considered for the present analysis were derived
from the Vaud Cancer Registry dataset, which includes in-
formation concerning incident cases of malignant neoplasms
occurring in the canton (about 530,000 inhabitants in 1980)(Levi, 1982, 1987).
Notification is based on a voluntary agreement between
the recording medical institutions of the canton and the
registry. All hospitals, pathological laboratories and most
practitioners are asked to report all new or past cases of
cancer. The main source of notification is the Cantonal
University Pathological Department of Lausanne which per-
forms the majority of histological examinations for the
population covered by the Registry.
The main information available from the register com-
prises sociodemographic characteristics of the patient (i.e.
age, sex), primary site and histological type of the tumour
according to the standard International Classification of
Diseases for Oncology (ICD-O), and time of diagnostic
confirmation (histological or clinical diagnosis).
Passive and active follow-up is recorded and each subse-
quent item of information concerning an already registered
case is used to complete the record of that patient. Infor-
mation coming from death certificate is added to the mor-
bidity file. Cases known only through the death certificate('Death Certificate Only' cases (DCO)) contribute less than
5% of the average number of new cases registered per year.
The registry is tumour based and multiple primaries occur-
ring in the same person are included separately whenever
morphologically different (according to the pathological re-
port) or occurring at different anatomical sites (defined at the
third-digit level of the ICD-O topographical code). However,
multiple non-melanomatous skin tumours are classified by
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the site of the first recognised tumour of the same mor-
phological type.
After exclusion of 1,416 (4%) cases diagnosed at autopsy
or by death certificate alone (811 and 605 among males and
females, respectively), the present series comprises a total of
34, 615 cases of first diagnosed cancer primaries (18,001 and
16,614 among males and females, respectively) registered
from 1974 to 1989 in the population of the Swiss canton of
Vaud.
Among these cases of incident neoplasms, followed-up to
the end of 1989 for a total of 118,241 person-years at risk,
there were 2,185 (1,280 males, 905 females) metachronous
(i.e. diagnosed at least two months after the first primary)
second primaries. Tumours occurring synchronously, accoun-
ting for about 25% of all the pairs of primaries, were ex-
cluded from the present analysis. Histological confirmation
was performed in 93% of the first as well as second primaries
considered.
Calculation of expected numbers was based on sex-, age-,
and calendar year-specific incidence rates multiplied by the
observed number of person-years at risk. The end of the
follow-up was determined by a second primary, death, emi-
gration or the end of the study period at 31 December 1989.
The significance of the observed/expected ratios (standardised
incidence ratio, SIR) was based on the exact Poisson dist-
ribution applied to the observed numbers (Breslow & Day,
1987).
Results
Table I gives the total number of second primary cancers
following any first primary site, and the corresponding SIR
for each selected cancer site and sex. Over the 14-year period
considered a total of 2,185 second primaries were registered
in the Vaud Cancer Registry (1,280 males, 905 females). For
both sexes, these figures were significantly elevated by about
20% (SIR 1.2 in both sexes). When specific cancer sites were
considered, significantly elevated rates were registered for
Table I Subsequent primary malignant tumour at selected sites, and
corresponding standardised incidence ratios (SIR), following any first
primary site in males and females. Vaud, Switzerland, 1974-1989
Site of second Males Females
primary tumour Observed SIR Observed SIR
Oral cavity and pharynx 59 1.6b 20 2.0b
Oesophagus 37 1.5b 8 0.9
Stomach 37 0.8 17 0.7
Colorectum 120 1.1 111 1.2
Liver 16 0.9 2 0.5
Gall bladder 8 1.1 12 0.9
Pancreas 18 0.7 18 0.9
Larynx 15 1.0 1 0.7
Lung 215 1.4c 27 1.1
Bone - - 1 1.9
Connective and soft tissue 6 2.2 8 2.0
Skin melanoma 24 1.7b 23 1.5
Skin non-melanoma 363 1.6c 262 1.5c
Breast 3 1.3 208 1.3c
Cervix uteri 9 0.5
Corpus uteri 31 0.9
Ovary 19 0.8
Prostate 161 1.0
Testis 6 2.2
Bladder 54 1.2 14 1.2
Kidney 27 1.5a 21 1.9b
Brain and nerves 4 0.6 3 0.6
Thyroid 6 2.4a 11 1.7
Lymphomas 32 1.2 23 1.2
Hodgkin's disease 2 1.0 3 1.5
Multiple myelomas 7 0.7 1 0.1
Leukaemias 23 1.2 12 0.9
All sites 1280 1.2c 905 1.2c
All sites, excluding
skin non-melanoma 917 1.2c 643 1.lb
a: P<0.05; b: P<0.01; C: P<0.001.
cancers of the oral cavity and pharynx in both sexes
(SIR = 1.6 for males, 2.0 for females), oesophagus and lung
in males (SIR= 1.5 and 1.4, respectively), skin melanoma
Table II Subsequent primary malignant tumours at selected sites,
and corresponding standardised incidence ratios (SIR), following
selected cancers for males and females in Vaud, Switzerland,
1974- 1989
Site of second Males Females
primary tumour Observed SIR Observed SIR
Site of first cancer: Oral cavity and pha
Any site* 95
Oral cavity and pharynx 21
Oesophagus 17
Larynx 4
Lung 37
Site of first cancer: Oesophagus
Any site* 7
Oral cavity and pharynx 3
Lung 3
Site of first cancer: Larynx
Any site* 55
Oral cavity and pharynx 8
Oesophagus 3
Lung 22
Site of first cancer: Lung
Any site* 72
Oral cavity and pharynx 7
Oesophagus 4
Lung 16
Site of first cancer: Stomach
Any site* 15
Skin, non-melanoma 6
Site of first cancer: Colorectum
Any site* 90
Colorectum 21
Prostate 25
Site of first cancer:
Skin melanoma
Any site* 16
Colorectum 5
Skin non-melanoma 6
Prostate 5
Site of first cancer: Skin non-melanoma
Any site* 336
Skin melanoma 18
Skin non-melanoma 223
Site of first cancer: Breast
Any site*
Colorectum
Pancreas
Breast
Corpus uteri
Ovary
Thyroid
Site of first cancer: Cervix uteri
Any site*
Colorectum
Lung
Site of first cancer: Corpus uteri
Any site*
Colorectum
Breast
Site of first cancer: Ovary
Any site*
Stomach
Colorectum
Breast
Corpus uteri
Site of first cancer: Prostate
Any site* 91
Colorectum 18
Stomach 10
Lung 18
Skin non-melanoma 29
Bladder 11
Kidney 3
Lymphomas 6
Leukaemias 6
Lrynx
3.4c
3.3c
L9.7c
6.6b
6.4c
1.1
9.6b
2.4
3.Oc
7.6c
5.3a
5.7c
1 .7c
2.8a
3.1a
1 .7a
0.8
1.4
1.2
1.9"
1 .5a
1.1
2.6a
1.4
2.0
1.0
3.0c
2.2c
0.7
1.0
1.3
0.8
0.8
1.5
1.1
1.5
1.9
20
9
2
0
3
2
0
0
2
1
0
12
3
0
2
2.9c
77.4c
20.7b
10.5b
1.3
1.5
41 .6a
16.5
2.6b
36.IC
9.6a
2 0.2
18 4.1c
63 1.1
14 1.5
13 0.8
1 0.4
18 4.1C
189 1.0
12 2.3b
112 1.9c
187 1.2b
26 1.1
7 1.4
75 1.7c
12 1.2
6 0.9
4 2.2
33 1.6b
4 1.4
7 7.8C
41 1.0
11 1.7
15 1.3
15 1.4
3 7.6b
2 1.2
5 1.5
2 2.7
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Table II - continued
Site of second Males Females
primary tumour Observed SIR Observed SIR
Site of first cancer: Bladder
Any site* 32 1.1 5 0.9
Lung 9 1.6 0
Prostate 10 1.8
Kidney 4 5.8b 2 19.6b
Site of first cancer: Kidney
Any site* 16 1.2 6 1.2
Skin non-melanoma 4 1.1 4 2.8
Prostate 4 1.7
Bladder 5 7.2c 3 30.Oc
Site of first cancer: Lymphomas
Any site* 29 1.3 12 1.0
Lung 12 2.8b 1 2.1
Skin non-melanoma 11 1.8a 12 3.6c
Site of first cancer: Leukaemias
Any site* 18 l.7a 12 2.5b
Lung 6 3.0a 0 _
Skin non-melanoma 9 3.0b 4 2.9a
*Non-melanoma skin cancer excluded. a: P<0.05; b:p< 0.01;
c: P<0.001.
(SIR = 1.7 for males, 1.5 for females), non-melanomatous
skin cancers (SIR = 1.6 for males, 1.5 for females), female
breast (SIR= 1.3), kidney (SIR= 1.5 for males, 1.9 for
females), and thyroid in males (SIR = 2.4).
Table II considers the incidence of selected subsequent
primary neoplasms following each separate cancer site. The
SIR following a cancer of the oral cavity and pharynx was
around 3 in both sexes (based on 95 males and 20 females),
and was mainly due to a substantial excess of subsequent
primaries in the oral cavity (SIR = 13 for males), oesophagus
(SIR around 20 for both sexes), larynx and lung (SIR over 6
for males). The incidence of subsequent primary neoplasms
was only slightly above unity following oesophageal cancer,
also on account of the extremely low survival rates, and
hence limited man-years at risk, from this neoplasm. In
males, this excess was due to cancers of the oral cavity and
pharynx (significant) and lung. A total of 55 males had a
subsequent primary following laryngeal cancer. The overall
SIR for all neoplasms was 3.0, and significant excesses were
observed for oral cavity or pharynx (SIR = 7.6), oesophagus
(SIR = 5.3) and lung (SIR = 5.7). The number of second
primaries following lung cancer was 72 among males (SIR =
1.7) and 12 among females (SIR= 2.6). In both sexes, a
significantly elevated SIR was observed for cancers of the
oral cavity and lung, and in males of the oesophagus, too.
With reference to second primaries following cancers of the
stomach and colorectum, no overall excess was observed for
all sites, but elevated SIRs were apparent for skin non-
melanoma following gastric cancer, and for large bowel and
prostatic cancer following colorectum.
A total of 16 males and 13 females experienced a second
neoplasm following skin melanoma. Significant excess ratios
were observed for colorectum in males (SIR = 2.6) and skin
non-melanoma in females (SIR= 4.1). The numbers of se-
cond tumours were much larger for non-melanomatous skin
cancers (336 males, 189 females), but the SIR for all sites was
exactly 1.0 in both sexes. Significantly elevated SIRs were,
however, observed for skin melanoma (SIR = 3.0 in males,
2.3 in females) and non-melanoma (SIR around 2 in both
sexes).
With reference to second primaries following breast and
female genital tract neoplasms, the incidence of any cancer
following breast cancer was significantly elevated (SIR = 1.2),
mainly on account of an elevated risk of subsequent breast
cancer (SIR = 1.7). With reference to cervical cancer, the SIR
was significantly elevated for any subsequent primary(SIR = 1.6) as well as for lung cancer (SIR = 7.8, based on
seven cases). No overall excess of second primaries was
observed after endometrial and ovarian cancer, although the
incidence was (non-significantly) elevated for colorectal and
breast cancers.
With respect to selected second primaries following urinary
tract (bladder and kidney) and prostate cancer, significantly
elevated SIRs were observed for kidney following bladder
cancer (SIR = 5.8 in males and 19.6 in females, based on 4
and 2 cases, respectively), and for bladder following kidney
(SIR = 7.2 in males and 30.0 in females, based on 5 and 3
cases, respectively). A total of 91 second primary neoplasms
were registered among first occurring prostate neoplasms. No
significant excess risk was observed, although SIR were
above unity for stomach (SIR = 1.3), bladder (SIR = 1.5),
lymphomas (SIR = 1.5) and leukaemias (SIR = 1.9).
Finally, second primaries were considered following leu-
kaemias and lymphomas. In both sexes, the incidence of
cancers of any site was significantly elevated following leu-
kaemia (SIR= 1.77 in males, 2.5 in females), with a
significant excess for lung in males and of non-melanomatous
skin cancers in both sexes. Likewise, following lymphomas,
there was an excess of lung cancers in males (SIR = 2.8), and
of non-melanomatous skin in both sexes.
Discussion
The present work has mainly a descriptive value, and pro-
vides further quantification on a population-based dataset of
the subsequent risk of various (second metachronous) pri-
mary cancers following any specific neoplasm. Its main value
lies in the fact that only a few similar series have been
published (Curtis et al., 1985; Storm et al., 1985; Teppo et
al., 1985), and hence the contribution of this study, at least in
quantitative terms of risk assessment, can be relevant. A
further interest of the present dataset derives from the strict
criteria adopted for the definition of second primaries, and
the practically total histological confirmation and revision
(Levi et al., 1982, 1987). An important limitation of the
study, however, is due to the relatively limited size of the
present study population and of the length of the follow-up,
and hence of the total number of multiple primary cancers
examined, at least in comparison with similar studies from
Connecticut (Curtis et al., 1985), Denmark (Storm et al.,
1985), or Finland (Teppo et al., 1985).
Another potential limitation of this study design is related
to problems of registration of second cancers. Although these
problems are reduced by an active follow-up of all registered
cases (Levi et al., 1989b), registration may be incomplete for
some site, such as non-melanoma skin cancers. Therefore,
non-melanoma skin cancer was excluded from the total
number of second primaries following each separate first
primary (Table II). Still, even for skin cancer registration this
is a privileged and particularly well surveilled population
(Levi et al., 1988a). Some caution in the interpretation is also
important, since over 1,000 comparisons were made, and
hence some significant results are bound to occur by change
alone.
Some of the associations emerged can be related to com-
mon risk factor exposure. For instance, the generally elevated
risk of multiple primaries of the upper digestive and res-
piratory tract should be related to tobacco and alcohol con-
sumption (Tuyns et al., 1977; Franceschi et al., 1990), and
viewed against the baseline high rates of these neoplasms in
French-speaking Switzerland (Levi et al., 1989a). Tobacco
consumption may also explain the excess of these neoplasms
following lung cancer, and the elevated incidence of lung
cancer following bladder and (probably) cervical cancer (US
Department of Health and Human Services, 1982; IARC,
1986), although it is not obvious to explain, on this basis
alone, the elevated leukaemia risk (Kabat et al., 1988; Kinlen
& Rogot, 1988).
In some instances tumours with different aetiologies may
simply appear significantly associated because they share
similar social class correlates. Along this line, the excesses of
cancer of the colorectum and prostate subsequent to a diag-
nosis of skin melanoma, may be interpreted, at least in part,
in terms of the more elevated prevalence of these three
neoplasms in the highest social classes in Switzerland (Levi et
al., 1988b).
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Other associations are well known, although quantifi-
cation, again, may be of some interest. For instance, the risk
of metachronous second primary breast cancer was elevated
by 70% on a population (publick health) level, but the real
excess risk for epidemiological and etiological inference is
probably double, since most women have only one breast at
risk following surgery for breast cancer (Peto, 1987). The
excess breast cancer incidence following primary ovarian
cancer may be due to genetic susceptibility (Parazzini et al.,
1992), besides common aetiological correlates (Franceschi,
1989). The association between multiple colorectal cancers,
kidney and bladder cancer and melanoma and non-melano-
matous skin cancers may be due to the action of common
risk factor exposure, but also to the increased surveillance
following a cancer diagnosis, which may be of particular
relevance for skin neoplasms and explain the association of
non- melanomatous skin cancer with other neoplasms (e.g.,
leukaemias).
In general, and in conclusion, the overall excess risk of a
second primary cancer is relatively limited (about 20% in
both sexes), and at least in part attributable to increased
surveillance. Thus, the true excess risk, due to risk factor
exposure or the consequences of treatment of the first neo-
plasm is even lower and, on a population level, of limited
public health importance for most cancer sites. Noteworthy
exceptions are represented by tumours of the upper aero-
digestive tract where more than 5-to-10 fold increased cancer
risks are common and clearly would justify special preventive
and therapeutical efforts.
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